CONFERENCE UPDATE: ASCO 2022

SHINE: Primary results of ibrutinib in combination with bendamustine-rituximab and rituximab maintenance in untreated MCL

HEMATOLOGY ONCOLOGY
29 Jul 2022

Glossary: 2L: Second-line; BR: A combination of bendamustine and rituximab chemoimmunotherapy; BTKi: Bruton's tyrosine kinase inhibitor; CI: Confidence interval; CR: Complete response; HR: Hazard ratio; MCL: Mantle cell lymphoma; MIPI: Mantle cell lymphoma Internation Prognostic Index; MR: Rituximab maintenance; NR: Not reached; OS: Overall survival; PD: Progression disease; PFS: Progression-free survival; PR: Partial response; Q8W: Every 8 weeks; QID: Four times a day; RR: Response rate; TEAE: Treatment-emergent adverse event; TTNT: Time-to-next treatment

Get access to our exclusive articles.
Related Articles

Transforming MCL care: The potential role of BTKi-based regimens in front-line treatment

At a recent symposium hosted by the Hong Kong Society of Haematology (HKSH) that discussed the current and future trends of the management of mantle cell lymphoma (MCL), Professor Simon Rule presented topics related to the trend of MCL management, the prognostic risk factors, and the risk stratifica
HEMATOLOGY
06 Sep 2023

ALR triple regimen elicits a high CR rate among patients with treatment-naïve MCL and allows treatment de-escalation with real-time RMD monitoring

HEMATOLOGY
08 Mar 2023

First-line ibrutinib shows similar or superior efficacy to standard immunochemotherapy + ASCT in younger MCL patients: The triangle trial
HEMATOLOGY
31 Jan 2023

Bruton’s tyrosine kinase inhibitors delay disease progression and extend survival in patients with relapsed/refractory mantle cell lymphoma

Mantle cell lymphoma (MCL) is a B cell malignancy that is typically clinically aggressive with a poor prognosis.1 When MCL patients progress into relapsed/refractory MCL (RRMCL), the median overall survival (OS) is usually reduced to around 1 year. Currently, three Bruton’s tyrosine kinase inhibitor
HEMATOLOGY ONCOLOGY
30 Dec 2020

Optimizing therapy in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an uncommon but aggressive subtype of lymphoid malignancy, generally considered to have a poor prognosis.1 Although the disease responds well to initial treatment, relapse will inevitably occur,1
HEMATOLOGY ONCOLOGY
28 Feb 2019